Treatment of C. difficile Infection in 2018:
What Do the New IDSA-SHEA Guidelines Recommend?
Tuesday, May 15, 2018
1:00 - 2:00 PM ET

The incidence of Clostridium difficile infection (CDI) has been growing steadily and has become the most common cause of healthcare-associated infection in adults in the United States.

It had been more than a decade since the last clinical practice guideline for CDI was released. A panel of experts convened by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA) updated the 2010 guideline and released the report February 15, 2018. It includes significant changes in the management of CDI and addresses the evolving controversy over the best methods for diagnosis. The new guideline also incorporates recommendations for children.

This activity is accredited for nurses, physicians, laboratory directors, quality care coordinators and all healthcare professionals involved in the prevention, detection, diagnosis, and reporting of C. difficile.

The webinar will be available on-demand after the live portion with downloads of the transcript and educational slides posted (see Downloads). There is no charge for this activity.

Planned and developed by Medavera, Inc. and supported by an educational grant from Abbott.

Professor of Medicine
Harvard Medical School
Chief, Herrman L. Blumgart
Internal Medicine Firm
Fellowship Training Medical
Director, Celiac Center
Beth Israel Deaconess Medical Center
Boston, Massachusetts

Dr. Kelly earned his medical degree from Trinity College (Dublin) where he was a Foundation Scholar and recipient of numerous academic awards. Dr. Kelly has received postgraduate clinical and research awards from the Crohn's and Colitis Foundation of America, the American Gastroenterological Association and the National Institutes of Health. He is an American Gastroenterology Association Fellow and a Fellow of the American College of Gastroenterology.

Dr Kelly’s longstanding clinical and research interests in intestinal infection and inflammation. He has been involved in patient care and research in Clostridium difficile infection for more than 30 years and has lead NIH-funded research programs. He has served as a committee member of the NIH, Center for Scientific Review as well as FDA, CDC and NIH committees related to initiatives to prevent and treat C. difficile infection. He has authored more than 200 peer-reviewed publications/invited reviews and clinical and basic science research book chapters.

Associate Professor of Pathology
Medical Director, Clinical Microbiology Laboratory
Duke University Health System
Durham, North Carolina

Dr. Polage earned his medical degree from the University of New Mexico where he was a post sophomore pathology fellow and got his start in infectious diseases research. He completed a clinical internship in Internal Medicine at the University of Colorado and residency training in anatomic and clinical pathology at the University of Utah followed by a two year Medical Microbiology fellowship at ARUP Laboratories. He currently directs the clinical microbiology laboratory for the Duke University Health System.

Dr. Polage has been actively engaged in outcomes and healthcare systems research related to the diagnosis and prevention of Clostridum difficile infection since 2010. In 2016, he received the a Distinguished Clinical Research Achievement Award from the Clinical Research Forum for his outcome studies of hospitalized patients with discrepant test results for Clostridum difficile infection. In 2017, he was recognized as a Choosing Wisely Champion by the American Society for Clinical Pathology (ASCP). He currently serves on the Editorial Board for the Journal of Clinical Microbiology and co-authored a point-counterpoint discussion regarding the pros and cons of different diagnostic approaches for C. difficile infection for this journal last year (2017).

Associate Professor, Pathology & Immunology
Program Director,
CPEP Program in Medical
and Public Health Microbiology
Washington University School of Medicine
St. Louis, Missouri

Dr. Burnham’s focus is on developing and testing new approaches for identifying microorganisms that cause disease.

Dr. Burnham’s research has focused on improvement of diagnostic methods for clinical microbiology. She is interested in antimicrobial resistance, with a focus on the transmission and epidemiology of multidrug resistant organisms (MDROs); Burnham has conducted collaborative research on Clostridium difficile and methicillin-resistant Staphylococcus aureus. She is a board-certified medical microbiologist and is the medical director of the Clinical Microbiology Laboratory for Barnes-Jewish Hospital, and the program director for Washington University in St. Louis’ CPEP accredited Fellowship in Medical and Public Health Microbiology.

Dr. Burnham has been named to the American Society for Clinical Pathology’s 40 Under Forty list of accomplished pathologists and laboratory medicine professionals. The list recognizes early-career scientists and clinicians whose achievements and leadership qualities are making an impact on pathology and laboratory medicine.

Tuesday, May 15, 20181:00 - 2:00 pm ET
1:00 to 1:05 pm
Welcome and Introductions
Professional Moderator
1:05 to 1:20 pm
State of the Union: The New C. diff Guidelines
Ciarán P. Kelly, MD, AGAF, FACG
1:20 to 1:35 pm
Finding Goldilocks: Which Diagnostic Testing Is Just Right?
Christopher R. Polage, MD, MAS
1:35 to 1:50 pm
The Evolution of Testing Methods for C. difficile Infection
Carey-Ann D. Burnham, PhD, D(ABMM)
1:50 to 2:00 pm
Panel Discussion
Question and Answer Session
1.Review new guidelines for C. difficile detection, diagnosis, and treatment
2.Assess the potential for overdiagnosis of CDI
3.Evaluate CDI testing methodologies and reporting of results
4.Apply findings to determine the appropriate protocol and testing algorithms for CDI for one’s institution

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through PeerPoint Medical Education Institute, LLC. PeerPoint is accredited by the ACCME to provide continuing medical education for physicians.

PeerPoint designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit(s)™ toward the AMA Physician’s Recognition Award. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Educational Review Systems is an approved provider of continuing nursing education by the Alabama State Nursing Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. Provider # 5-115. This program is approved for 1 hour of continuing nursing education. Educational Review Systems is also approved for nursing continuing education by the state of California, the state of Florida and the District of Columbia.

Educational Review Systems is an approved provider by P.A.C.E. This program is approved for 1 hour of CE credit.

Florida practitioners will need to self-report credits for this program to their CE Broker profile.

Please register for this webinar to view.
Medavera is a leader in medical education. Our team of experienced medical and scientific professionals identifies gaps in knowledge and care, methodically researches the subject matter, identifies the top experts to guide the content and utilize formats that will provide the best learning opportunity. Great content, respected leaders, and user-friendly platforms create successful interactions and learning.
© Medavera, Inc. 2019. All rights reserved.